What Synbio Technologies does

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou Industrial Park with a US operating entity; listed on China's NEEQ as 871854) operates an integrated synthetic biology Design-Build-Test-Learn (DBTL) platform serving academic researchers, biopharmaceutical developers, and industrial biotech customers across more than 20,000 global accounts. Its service portfolio is anchored by two flagship brands — Syno®C oligo/primer synthesis and Syno®GS gene synthesis — and extends into mRNA/RNA synthesis, a CRISPR gene editing platform with off-the-shelf and custom sgRNA libraries, viral packaging (lentivirus, AAV, adenovirus), multi-host recombinant protein expression (prokaryotic, yeast, baculovirus-insect, mammalian, cell-free), an antibody engineering platform, peptide services, sequencing and omics analysis (including a newly launched metabolomics service), and bioinformatics design tools. One-stop solutions layer on top of these for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening.

The company's technology stack includes proprietary NGCodon™ AI codon optimization (described as patented), chip-based Fragment XP DNA fragment synthesis, recombination-deficient host workflows for high-difficulty sequences (hairpins, long inverted repeats), and ProXpress point-of-use protein detection cards that compress synthesis-to-verification cycles. The commercial model combines quote-based custom professional services for enterprise biopharma with a catalogue of ready-made products (e.g., recombinant humanized collagen Pichia pastoris strains, CRISPR plasmids, recombinant proteins, Syno® adapters/blockers/hybrid capture probes). Distribution is hybrid: direct enterprise sales and self-serve LIMS ordering in China, a US operating entity, and a strategic global distribution partnership with VWR for worldwide reach. Strategic partnerships with Porton Biologics (CRDMO), BOE Sensor (hardware), and YanYin Technology (ecosystem) extend the platform's scope, and the company was recognized as a 2024 Jiangsu Province Specialized & Sophisticated SME.

Name

Synbio Technologies

Legal name

苏州泓迅生物科技股份有限公司

Website

https://synbio-tech.com.cn

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Synbio Technologies is a Suzhou-headquartered synthetic biology services company (founded 2013, listed on NEEQ 871854) operating an integrated DNA/RNA synthesis, CRISPR, viral packaging, and multi-host protein expression platform serving 20,000+ academic and biopharma customers globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Suzhou Shi

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Custom synthesis services: Project-based revenue from custom gene synthesis, oligo synthesis, RNA synthesis, mRNA synthesis, peptide synthesis, gene library construction and CRISPR library customization, with service levels ranging from milligram to kilogram scale protein production. Pricing varies by complexity and length (e.g., "Second Generation Gene Synthesis" launched at promotional RMB 258 for <416bp).
2. Catalogue product sales: Direct sales of off-the-shelf products including CRISPR libraries (human, mouse, monkey, poultry, livestock, microbial), recombinant protein strains (humanized type I/III collagen Pichia pastoris strains, human fibronectin Pichia pastoris strain, human serum albumin strain, biosynthetic bilirubin, fluorescent modified bacterial strains), ProXpress protein rapid test cards, CRISPR plasmids (knockout vectors, high-throughput gene editing vector libraries), and oligos (monkeypox primer probe, CpG-ODN, Syno® Adapters/Blocker/Hybrid Capture Probe).
3. Global distribution via VWR: Channel/distributor revenue stream through strategic distribution agreement with VWR (global laboratory products and services provider), extending reach to worldwide customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Core offering

Synbio Technologies operates an integrated synthetic biology DBTL (Design-Build-Test-Learn) service platform delivering custom DNA/RNA synthesis, CRISPR gene editing, recombinant protein expression, antibody engineering, viral packaging, peptide synthesis, sequencing/omics, and bioinformatics. Its commercial catalogue includes ready-made CRISPR libraries, recombinant yeast/bacterial strains (e.g., humanized collagen Pichia pastoris strains, biosynthetic bilirubin), CRISPR plasmids, finished oligos, and ProXpress lateral-flow protein rapid detection cards. Revenue is generated through project-based custom services and direct catalogue product sales distributed globally via a VWR partnership.

Product overview

Synbio Technologies (苏州泓迅生物科技股份有限公司, founded 2013, headquartered in Suzhou with US operations) operates a multi-platform synthetic biology technology stack organized as a Design-Build-Test-Learn (DBTL) integrated solution. The portfolio is anchored by two flagship service brands — Syno®C primer/oligo synthesis and Syno®GS gene synthesis — and extends into complementary platforms: RNA/mRNA synthesis, the CRISPR gene editing platform with off-the-shelf CRISPR libraries, virus packaging (lentivirus/AAV/adenovirus), a multi-host recombinant protein expression platform, an antibody engineering platform, peptide services, sequencing & omics (including the newly launched metabolomics service), high-throughput DNA library construction, and bioinformatics analysis & design. On top of these services, the company layers one-stop solutions for full-length recombinant collagen, small nucleic acid raw materials, recombinant protein expression, and CRISPR pooled screening. The commercial product catalogue includes ready-made synthetic biology strains (e.g., recombinant humanized collagen and serum albumin Pichia pastoris strains, MoClo-YTK modular yeast toolkit), CRISPR plasmids, recombinant proteins (Cas12, Protein A/G/L), finished oligos (Syno® adapters, blockers, hybrid capture probes), and the ProXpress point-of-use protein rapid test card line. AI capabilities (AI codon optimization via the proprietary NGCodon™ technology and AI-designed gene sequences) are embedded across the workflow.

Differentiator

Problem solved

Functional benefit

Brands

• Syno®C: Brand name for Synbio's DNA oligo / primer synthesis service line (常规引物合成, 超长引物合成, 修饰引物合成, 核酸探针合成, NGS引物合成, 简并引物合成, 核酸适配体合成, ASOs合成, Trimer引物合成, etc.).
• Syno®GS
• ProXpress
• NGCodon™
• Syno® Adapters / Syno® Blocker / Syno® Hybrid Capture Probe

Products and services

• Syno®C Primer/Oligo Synthesis

Quantifiable outcome

• Documented sgRNA library coverage >99% and uniformity <10 in mouse whole-genome CRISPR knockout case study
• +4 more outcomes

Named customers50 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Porton Biologics (博腾生物制药有限公司)coreStrategic or Co-development Partner · 6 May 2023Signed a CRDMO strategic cooperation agreement on 6 May 2023 in Suzhou to establish a new partnership. Synbio Technologies provides synthetic biology design-build platforms while Porton Biologics contributes CRDMO capabilities for gene and cell therapy development.
• VWRflagshipChannel Partner/ Reseller/ DistributorSynbio Technologies formally partnered with VWR, a global laboratory products and services giant, to enter VWR's distribution network. The partnership is positioned as a "global supply chain upgrade" enabling worldwide customers to access Synbio's molecular manufacturing capabilities.
• YanYin Technology (上海衍因科技有限公司)coreStrategic or Co-development PartnerSigned a comprehensive strategic cooperation agreement at Synbio's Suzhou headquarters to deepen collaboration in synthetic biology. Signed by Synbio VP Qi Jincai (齐金才) and YanYin CEO Chen Zeping (陈泽平). Focuses on joint synthetic biology ecosystem innovation.
• BOE Sensor (北京京东方传感技术有限公司)coreStrategic or Co-development PartnerAnnounced in March 2024 a deep strategic partnership with BOE Sensor to jointly explore new horizons in synthetic biology hardware equipment, leveraging a synthetic biology thinking framework. The collaboration targets innovation in upstream hardware used in synthetic biology workflows.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Thermo Fisher Scientific (GeneArt services): Global life sciences giant offering gene synthesis (GeneArt), oligo synthesis, protein expression, CRISPR reagents, and viral vector services as part of a much broader portfolio. Overlaps with multiple Synbio platforms and serves the same enterprise biopharma customer base.
• BGI Genomics: Largest Chinese genomics company with broad DNA sequencing, synthesis, and synthetic biology capabilities. Comparable on gene synthesis, sequencing, and synthetic biology tooling, with significantly larger scale and brand recognition in China and globally.

Direct peers

• ATUM (formerly DNA2.0): Synthetic biology company specializing in gene synthesis, protein engineering, and antibody optimization with an AI-driven codon optimization engine (similar positioning to NGCodon™). Directly comparable on gene synthesis and AI-optimized protein expression offerings.
• Twist Bioscience: Publicly traded leader in high-throughput silicon-based DNA synthesis and synthetic biology services, including gene fragments, genes, oligo pools, antibody libraries, and DNA data storage. Directly comparable on core gene/oligo synthesis offerings and similar academic/biopharma customer base, but at significantly larger scale.
• Integrated DNA Technologies (IDT): Major US-based provider of custom oligonucleotides, gene synthesis, CRISPR reagents, and NGS services, owned by Danaher. Closest direct competitor to Synbio's Syno®C oligo and Syno®GS gene synthesis lines, with overlapping academic/biopharma customers.
• GenScript: Global biotech with gene synthesis, recombinant protein expression, antibody engineering, peptide, and cell therapy services. Directly overlaps with Synbio's multi-platform DBTL offering, and operates significant capacity in both US and China.
• Synthego: US-based synthetic biology company specializing in gene synthesis, sgRNA synthesis, and CRISPR genome editing tools. Highly comparable to Synbio's CRISPR platform and gene synthesis core, with similar academic/therapeutics customer focus.
• Sangon Biotech (Sangon): Major Chinese synthetic biology and molecular biology services provider offering oligos, gene synthesis, protein expression, and CRISPR products. Headquartered in Shanghai and a primary China-based competitor to Synbio's full DBTL stack.
• Tsingke Biotechnology: Leading Chinese DNA synthesis and synthetic biology services provider offering gene synthesis, oligo synthesis, gene editing, and protein expression. Closest direct domestic peer to Synbio in the China synthetic biology services market.
• Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering oligo synthesis, gene synthesis, DNA sequencing, and CRISPR services. Synbio lists Eurofins as a customer but Eurofins Genomics is also a direct competitor in synthesis services globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/synbio_tech
• LinkedInlinkedin.com/company/synbio-technologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synbio Technologies